Eli Lilly halts new studies and exports of some medicines to Russia
Pharmaceutical firm Eli Lilly, a competitor to Novo Nordisk on the US insulin scene, says it is ethically bound to protect patients, even if they live in Russia, which is heavily sanctioned.
By Riley Griffin, bloomberg
Eli Lilly & Co. said it has suspended investment, promotional activity and new clinical trials in Russia, and has stopped exporting nonessential medicines to the country, in response to the war in Ukraine.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Novo Nordisk donates two months' worth of insulin to Ukraine
For subscribers
